Diffuse Peritoneal Mesothelioma is a rare disease. There is no epidemiological evidence about the cause except a small percentage of patients who are associated exposure to asbestos. There is no predominance in sex, age or race. Not a member no genetic association, dietary preference or geographical distribution. Usually occurs sporadically without family distribution.

Mesothelioma is unusual and may have a wide spectrum with different biological aggressiveness. The cystic variant can cause repeated episodes of abdominal pain but usually does not cause death of the patient. By contrast, the most aggressive forms may present in mesenteric lymph node metastases at the time of diagnosis. The number of mitosis, cell morphology and histological types determine the aggressiveness of the disease. But you can expect different types or levels of tumor mestotelial in the same patient.

Clinically, the diffuse dissemination of malignant mesothelial cells determines a copious production of liquid, so that all patients with peritoneal mesothelioma present with large amount of ascites at initial diagnosis.

Cytoreductive surgery and Perioperative Intraperitoneal Chemotherapy
Because the disease is maintained during its evolution intraabdominal long tiempoo, using the right combination of radical oncologic cytoreductive surgery through the practice of regulated peritonectomy visceral resection with or without a companion, always attached to the intraperitoneal chemotherapy is a perioeperatoria allows promising treatment option both from the standpoint of pharmacological and clinical.

Intraperitoneal Chemotherapy modulated by hyperthermia associated with early postoperative intraperitoneal Quimioterpia complete eradication of macroscopic disease is a strategy that promises to improve treatment outcomes of this disease.